NephroPlus (Nephrocare Health Services)
17 Dec '25MAINBOARD
Min. Investment
₹14,016
Issue size
₹871.05 Cr
GMP
Locked
Overall subscription: 13.71x
Check allotment status
Expert verdict
IPO dates
10 Dec
Opening
12 Dec
Closing
15 Dec
Allotment
17 Dec
Listing
*Refunds will be initiated on 16 Dec '25
IPO quota
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 32 | ₹14,720 |
| HNI (Min) | 14 | 448 | ₹2,06,080 |
Subscription (as on 16 March 2026, 06:30 PM)
Overall13.71x
Qualified institutional buyers
Non-Institutional Buyers
Retail Investors
Employee
About company
Founded: 2009|MD: Mr Vikram Vuppala
- Nephrocare Health Services provides dialysis care through a network of clinics, including in-clinic haemodialysis and other dialysis formats.
- It offers diagnosis-to-treatment support and wellness programs, home dialysis, mobile (dialysis on wheels), holiday dialysis, dialysis on call, and pharmacy support. The company also runs protocol-led dialysis practices across its clinics, uses cloud-enabled dialyzer reprocessing technology (Renova), and trains personnel through its academy (Enpidia).
- As of September 30, 2025, it operated 519 clinics globally: 468 in India and 51 outside India (41 in the Philippines, six in Nepal, and four in Uzbekistan). In India, its clinics covered 288 cities across 21 states and four Union Territories, with a large share located in tier II and tier III locations. It operates clinics in hospitals, standalone sites, and through public-private partnership (PPP) models.
- Use of proceeds:
- The IPO consists of both a fresh issue of shares and an offer for sale (OFS). Net proceeds from the OFS will go to the respective selling shareholders, while the net proceeds from the fresh issue will be utilised for the following purposes:
- Capital expenditure for opening new dialysis clinics in India—approximately Rs 129.11 crore.
- Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by the company—approximately Rs 136 crore.
- General corporate purposes.
Issue Details & Objective
Lot size
32 Shares
Price band
₹438 to 460
Face value
₹2 per share
Financials
Download DRHP (IPO Doc)FAQs
Our SEBI-registered investment advisors give out verdicts for each IPO. You can refer to their expert verdict at the top of this page. Please note that these verdicts are for informational purposes only and should not be construed as investment advice. Markets are subject to risk, and investors should exercise their own discretion and diligence.
The issue size of NephroPlus (Nephrocare Health Services) IPO is ₹871.05 Cr
The NephroPlus (Nephrocare Health Services) IPO will be open for applications from 10 Dec '25 to 12 Dec '25
The lot size of NephroPlus (Nephrocare Health Services) IPO is 32 Shares and its minimum investment amount is ₹14,016.
Grey market premium (GMP) is a premium amount at which grey market IPO shares are traded before they get listed in the stock exchange. The GMP for NephroPlus (Nephrocare Health Services) IPO is null
